Holen Sie sich die Stockscreener-App
65.92
0.23%
-0.15
Handel nachbörslich:
65.70
-0.22
-0.33%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ARWR?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$66.07
Offen:
$66.5
24-Stunden-Volumen:
1.62M
Relative Volume:
0.75
Marktkapitalisierung:
$9.31B
Einnahmen:
$622.01M
Nettoeinkommen (Verlust:
$-271.86M
KGV:
-30.68
EPS:
-2.1484
Netto-Cashflow:
$-45.87M
1W Leistung:
-0.84%
1M Leistung:
-25.83%
6M Leistung:
+8.47%
1J Leistung:
+108.21%
1-Tages-Spanne:
$65.40
$67.44
1-Wochen-Bereich:
$65.40
$72.49
52-Wochen-Spanne:
$31.45
$95.49
Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile
Firmenname
Arrowhead Pharmaceuticals Inc
Sektor
Branche
Telefon
626-696-4702
Adresse
177 E COLORADO BLVD, PASADENA, CA
Compare ARWR vs VRTX, REGN, MRNA, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ARWR
Arrowhead Pharmaceuticals Inc
|
65.92 | 9.31B | 622.01M | -271.86M | -45.87M | -2.1484 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-21 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-06-05 | Eingeleitet | Goldman | Neutral |
| 2023-12-04 | Eingeleitet | BofA Securities | Buy |
| 2023-09-19 | Eingeleitet | Citigroup | Neutral |
| 2023-07-21 | Eingeleitet | TD Cowen | Outperform |
| 2023-05-12 | Herabstufung | SVB Securities | Outperform → Market Perform |
| 2023-04-26 | Eingeleitet | SMBC Nikko | Outperform |
| 2023-04-12 | Hochstufung | SVB Securities | Market Perform → Outperform |
| 2023-03-21 | Eingeleitet | Bernstein | Mkt Perform |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-05-11 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-01-19 | Fortgesetzt | Goldman | Buy |
| 2021-08-06 | Bestätigt | Chardan Capital Markets | Buy |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Neutral |
| 2021-02-05 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-21 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-12-16 | Eingeleitet | UBS | Buy |
| 2020-11-19 | Eingeleitet | Citigroup | Buy |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-05-08 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-04-15 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2020-03-24 | Hochstufung | SVB Leerink | Underperform → Mkt Perform |
| 2020-03-17 | Eingeleitet | Goldman | Neutral |
| 2020-01-21 | Eingeleitet | SVB Leerink | Underperform |
| 2019-12-13 | Eingeleitet | Oppenheimer | Perform |
| 2019-11-29 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-11-27 | Bestätigt | B. Riley FBR | Buy |
| 2019-11-25 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2019-10-24 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2019-10-22 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-10-03 | Eingeleitet | Robert W. Baird | Outperform |
| 2018-09-07 | Hochstufung | B. Riley FBR | Neutral → Buy |
| 2018-09-06 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-08-08 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2018-07-02 | Bestätigt | Chardan Capital Markets | Buy |
Alle ansehen
Arrowhead Pharmaceuticals Inc Aktie (ARWR) Neueste Nachrichten
ARWR Stock On Track To Hit Over 5-Year Highs – Retail Cheers Phase 3 Breakthrough As Arrowhead Targets Broader FDA Approval - Stocktwits
Arrowhead Pharmaceuticals, Inc. (ARWR) Stock forecasts - Yahoo Finance UK
ARWR Stock: Goldman Sachs Resumes Coverage With $74 Target As Clinical Catalysts Near - finance.yahoo.com
Goldman Sachs initiates Arrowhead Pharma stock coverage with neutral rating By Investing.com - Investing.com South Africa
Goldman Sachs initiates Arrowhead Pharma stock coverage with neutral rating - Investing.com Canada
Arrowhead Pharmaceuticals, Inc. (ARWR) Stock Forecasts - Yahoo! Finance Canada
Arrowhead Pharmaceuticals Slides as Investors Reassess Recent ARO-DIMER-PA Data - quiverquant.com
Arrowhead Pharmaceuticals Drops 5.4% Amid Sector-Wide Selling - AlphaStreet
Arrowhead Pharmaceuticals, Inc. (ARWR) Stock Price, News, Quote & History - Yahoo! Finance Canada
Arrowhead Pharmaceuticals (ARWR) Stock Analysis: Unpacking A 59.91% Upside Potential - DirectorsTalk Interviews
Arrowhead Pharmaceuticals, Inc. (ARWR) stock price, news, quote and history - Yahoo Finance UK
Arrowhead Pharmaceuticals (ARWR) On ARO DIMER PA Data And Whether Undervaluation Still Holds - finance.yahoo.com
Arrowhead Pharmaceuticals Spotlights Dual-Target RNAi Data, Plozasiran Launch Progress - TradingView
Arrowhead Pharmaceuticals Eyes SHTG Filing as RNAi Pipeline Expands - finance.yahoo.com
Arrowhead Pharmaceuticals Inc. (ARWR) Key Financial Ratios – Valuation, Profitability & More - Value Research
Is Arrowhead Pharmaceuticals (ARWR) A Bargain On Strong ARO DIMER PA Trial Data? - simplywall.st
Analysts Offer Insights on Healthcare Companies: Arrowhead Pharmaceuticals (ARWR) and Envista Holdings (NVST) - The Globe and Mail
Arrowhead Pharmaceuticals Plans Supplemental Drug Approval Application - Intellectia AI
Not A ‘Gangbusters Launch’ — Arrowhead Predicts Slow Burn to $3B-$4B Peak For Redemplo, Highlights ‘Massive Pipeline’ - Yahoo Finance
Arrowhead Pharmaceuticals, Inc. rStock (RARWR) Price Prediction for 2026 to 2031 - Bybit
Arrowhead Achieves Clinical Validation for New Drug Platform - Benzinga
Arrowhead Tackles Two Targets To Lower Multiple ASCVD-Causing Lipids - insights.citeline.com
ARWR Stock Heads For Worst Day In Over A Year Despite Positive Cholesterol Drug Data — Is This A ‘Sell The News’ Move? - Yahoo Finance
Arrowhead Pharmaceuticals Inc Stock (ARWR) Moved Down by 8.93% on Sep 15: What Investors Need To Know - TradingKey
Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia - Yahoo Finance
How Investors May Respond To Arrowhead Stock Phase 3 Trial Results - webull.com
Avoiding Lag: Real-Time Signals in (ARWR) Movement - Stock Traders Daily
ARWR Looks 63.8% Overvalued on GF Value™ - GuruFocus
ARWR Stock Clocks Best Day In Nearly 8 Months As Analyst Lifts Price Target On Plozasiran Data - Stocktwits
Arrowhead Pharmaceuticals, Inc. (ARWR) Latest Stock News & Headlines - finance.yahoo.com
ARWR Initiated Coverage by Citigroup -- Price Target Announced a - GuruFocus
ARWR: SHASTA-3 and SHASTA-4 Data Presented at ESC 2026 - Yahoo Finance
Citigroup Initiates Arrowhead Pharmaceuticals at Buy With $108 Price Target - finance.yahoo.com
Arrowhead Pharmaceuticals Director Sells 11,600 Shares for $1 Million - Yahoo Finance
Arrowhead (ARWR) Reported a 78% Lower Pancreatitis Event Rate With Plozasiran. Does the Absolute Benefit Support a Broader Label? - Yahoo Finance
Arrowhead Pharmaceuticals to Participate in Upcoming September 2026 Investor Conferences - Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses SHASTA-3 and SHASTA-4 12-Month Results for Plozasiran in Severe HypertriglyceridemiaSlideshow (NASDAQ:ARWR) 2026-09-02 - Seeking Alpha
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at European Society of Cardiology (ESC) Congress 2026Slideshow (NASDAQ:ARWR) 2026-09-02 - Seeking Alpha
ARWR Reiterated by HC Wainwright & Co. -- Price Target Maintained at $120 - GuruFocus
Is Arrowhead Pharmaceuticals (ARWR) Undervalued As SHASTA 3 And SHASTA 4 Data Impress? - Yahoo Finance
Arrowhead Pharmaceuticals' sHTG Therapy Could Get FDA Approval by Q2 2027, RBC Says - marketscreener.com
Arrowhead’s Plozasiran Cuts Triglycerides, Pancreatitis Risk in Phase 3 Trials - Yahoo Finance
Stifel reiterates Buy rating on Arrowhead Pharma stock at $104 - Investing.com
Arrowhead’s new Redemplo findings in severe hypertriglyceridemia have analysts split - biospace.com
Arrowhead Pharmaceuticals' Plozasiran Meets Endpoints in Studies of Patients With Severe Hypertriglyceridemia - marketscreener.com
Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia - Investing News Network
Arrowhead’s plozasiran cuts pancreatitis events in Phase 3 studies (ARWR:NASDAQ) - Seeking Alpha
Could Arrowhead Pharmaceuticals (ARWR)’s Plozasiran Become the Catalyst for a Major Stock Re-rating? - finance.yahoo.com
Arrowhead Pharmaceuticals to Present New Clinical Data at the European Society of Cardiology Congress - Business Wire
Don't Ignore The Insider Selling In Arrowhead Pharmaceuticals - Moomoo
Arrowhead Pharmaceuticals director sells $173,920 in stock - Investing.com
Finanzdaten der Arrowhead Pharmaceuticals Inc-Aktie (ARWR)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.06%
2.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):